Výsledky vyhledávání - "E. Durak Ediboglu"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

AB0865 The Factors affecting patient global assesment in patients with Axial Spondyloarthritis

Autor: E. Durak Ediboglu, D. Solmaz, H. Cinakli, G. Alp, E. Otman Akat, E. Erpek, İ. Kurut Aysin, S. Gucenmez, S. Ketenci, O. Bayindir, M. Ozmen, S. Akar

Publikováno v: Annals of the Rheumatic Diseases. 81:1555.3-1556

BackgroundThe BASDAI is one of the basic scales used in the measurement of disease activity in patients with spondyloarthritis and allows the evalution of various aspects of the disease (axial and peripheral disease as well as inflammation). The pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f010a93548926173dd9fc2dc99949777
https://doi.org/10.1136/annrheumdis-2022-eular.4356

Zobrazit plný text záznamu

AB0643 Are there any distinctive finding in ANCA-associated vasculitis related pulmonary involvement in comparison with Connective Tissue Diseae or Idiopatic pulmonary fibrosis

Autor: E. Durak Ediboglu, Ş. Karasu, T. Ekici, M. O. Turan, Ö. Gerçik, D. Solmaz, C. Gümüş, S. Akar

Publikováno v: Annals of the Rheumatic Diseases. 81:1448.2-1448

BackgroundPatients with ANCA associated vasculitis (AAV) have a wide spectrum of pulmonary involvement from parenchymal necrotizing granuloma formation, trecheobronchial inflammation, pulmonary capillaritis to interstitial lung disease. Pulmonary inv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7771847244c7c2dff3a589b9c0c7aa0c
https://doi.org/10.1136/annrheumdis-2022-eular.5171

Zobrazit plný text záznamu

AB0773 Serum VEGF level may be have a role in the evaluation of treatment response and disease activity during TNFi therapy in patients with AxSpA

Autor: M. Gulec Yazir, E. Durak Ediboglu, G. Alp, H. Cinakli, İ. Kurut Aysin, E. Erpek, E. Otman Akat, S. Gucenmez, M. Ozmen, S. Ketenci, O. Bayindir, D. Solmaz, S. Akar

Publikováno v: Annals of the Rheumatic Diseases. 81:1512.2-1513

BackgroundPatient reported outcomes (BASDAI and BASFI) are used to evaluate disease activity in axial spondylarthritis (axSpA), however, apart from C-reactive protein (CRP) there are no widely used serum biomarkers to assess disease activity and trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd7dcdc5cd756032f6a937d4dab80a7f
https://doi.org/10.1136/annrheumdis-2022-eular.4305

Zobrazit plný text záznamu

POS1008 FACTORS ASSOCIATED WITH HIP INVOLVEMENT AND ITS IMPACT ON TREATMENT DECISION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS; TREASURE EXPERIENCE

Publikováno v: Annals of the Rheumatic Diseases. 81:812.2-813

BackgroundAxial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting sacroiliac joints, spine and peripheral joints. In addition to spinal and peripheral manifestations, root joints (hip or sholder) involvement may also dev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5a65de3a71d7968cda261035d7f6e630
https://doi.org/10.1136/annrheumdis-2022-eular.4962

Zobrazit plný text záznamu

AB0420 UNINTENTIONAL MONOTHERAPY IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING TOFACITINIB AND DRUG SURVIVAL RATE OF TOFACITINIB

Publikováno v: Annals of the Rheumatic Diseases. 81:1338.1-1338

BackgroundCombination of MTX with a bDMARDs or tsDMARDs is considered the most effective treatment regimen currently available for patients with RA who have failed to respond to conventional DMARDs. However, approximately 30% of patients receive bDMA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::38e24dce53ad355056d1e4f2b1add31c
https://doi.org/10.1136/annrheumdis-2022-eular.5102

Zobrazit plný text záznamu

POS1165 Lifestyle And Mood Changes In Axspa Patients During The Quarantine Period

Autor: S. Gucenmez, H. Cinakli, E. Erpek, Mustafa Özmen, Servet Akar, Dilek Solmaz, E. Otman Akat, G. Alp, G. Kabadayi, E. Durak Ediboglu, I. Kurut Aysin, O. Bayindir

Publikováno v: Annals of the Rheumatic Diseases. 80:861-862

Background:On March 11, 2020, the World Health Organization declared coronavirus disease 2019 (COVID-19) as a pandemic, and mandatory quarantine was applied in Turkey between April and June 2020. With this sanction, sudden changes occurred in a routi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3836ff1e37b6def9563927675fdbf80e
https://doi.org/10.1136/annrheumdis-2021-eular.592

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

AB0456 HYDROXYCHLOROQUINE MIGHT REDUCE MORTALITY IN PATIENTS WITH SYSTEMIC SCLEROSIS

Autor: S. Gucenmez, H. Cinakli, G. Alp, E. Durak Ediboglu, O. Bayindir, E. Otman Akat, Dilek Solmaz, G. Kabadayi, Servet Akar, I. Kurut Aysin, E. Erpek, Mustafa Özmen

Publikováno v: Annals of the Rheumatic Diseases. 80:1255.1-1255

Background:Systemic sclerosis (SSc) is a devastating disease that has a profound impact on life expectancy, reflected by a standardised mortality ratio of 3,5. There is still limited data regarding the predictive factors for mortality in patients wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1713aecae1b1b974c75e82d2dee735a2
https://doi.org/10.1136/annrheumdis-2021-eular.3685

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání